Genmab — December 2014
-
One hundred percent of newly diagnosed patients in the first three treatment arms responded to treatment with a very good partial remission or a partial remission. Fifty percent of patients in the relapsed group responded, which included one patient who achieved a complete remission and two who achieved very good partial remissions.
-
Researchers noted the only toxicities associated with the addition of daratumumab to the backbone regimens were infusion-related reactions in four patients. Most infusion-related reactions were grade 1, occurred on the first day of treatment and resolved with treatment. There were two cases of rash and one case of bronchospasm.
-
-
Også høje responsratr både VGPR og PR. Men igen undrer jeg mig over ingen CR.
-
Patienterne har været i studiet i omkring 16 uger i gennemsit. og ingen CR, ikke engang i front line patienter
-
Sorry der er et sCR så vidt jeg kan se
-
Samme konklusion som før. Flotte responstal men knap så dybe responser som jeg havde troet
-
Og bar lige for at understreje. Syntes ikke data er dårlige. Havde bare lidt højere forventninger jf. de data vi fik til ASCO
-
Kun lige skimmet præsentationerne, men enig med 1989 i at ORR ser rigtig fin ud, mens de helt dybe responser udebliver (altså CR), men spørgsmålet er om der er en forklaring på dette. Desuden er spørgsmålet også hvor stor klinisk betydning det har om man får et VGPR eller CR.
-
dara-len-dex data er supergode. iv89, du må regne med at de eneste data der er modne er fase1 delen, der har du dine CR og ORR 100%. De skriver at de venter fase2 delen udvikler sig tilsvarende.
-
Nu læste jeg det i nat, men mener der stod "median time to CR 6months"
-
Same goes for multicombo studiet. Opfølgningstiden er for kort til CR, Dara virker åbenbart langsomt, men dybt. Det sagde hun også igår...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind